ClinicalTrials.gg
TerminatedNCT05886491Updated Sep 25, 2026Results posted

A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1/2 interventional study of GDX012 and Chemotherapy Agents in Leukemia, sponsored by Takeda. Terminated at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Primary conditionLeukemia, Myeloid, AcuteRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myeloid, Acute
Why
  1. The study's title name Leukemia, Myeloid, Acute, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision (No safety concern)
Updated Sep 25, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Leukemia, Myeloid, Acute by Takeda — none open to participants now, none under way, none of them phase 3. Leukemia, Myeloid, Acute · Takeda.

Enrollment
12th of 13
16 · median 60
Started
2023
the only one that year
Phase 1/2
2 of 14
none open now
Registered
14th of 14
by date

Among the 14 studies in Leukemia, Myeloid, Acute by Takeda, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 1/2, and was the 14th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

None of the 14 studies in Leukemia, Myeloid, Acute by Takeda is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Leukemia, Myeloid, Acute by Takeda as a file.
02

Study summary

GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and to determine the best dose of GDX012.

Read the detailed description

The drug being tested in this study is called GDX012. GDX012 is being tested to evaluate the safety and tolerability in adult participants with AML.

The study will enroll approximately 53 patients in two phases, dose escalation and dose expansion.

During Phase 1 (sequential dose escalation), participants will be assigned to one of the following treatment groups each consisting of 3 to 6 participants to receive GDX012 at one of the three dose levels:

  1. GDX012 Dose 1
  2. GDX012 Dose 2
  3. GDX012 Dose 3

Upon completion of Phase 1, 1 to 2 dose levels will be selected for Phase 2a of the study. At the completion of Phase 2a of the study a single dose may be selected by the sponsor and investigators as the recommended phase 2 dose (RP2D) for future study.

This multi-center trial will be conducted in the United States and Japan. The overall time to participate in the study is approximately 14 months.

03

Conditions studied

  • Leukemia

Browse trials for

Keywords

  • Drug Therapy
  • AML
  • acute myeloid leukemia
  • cell therapy
  • allogenic
  • gamma delta T cells
  • relapsed/ refractory
04

In context

Leukemia, Myeloid, Acute Reclassified

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

This study's enrollment of 16 is below the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 155 (87%) have results posted.

Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Total body weight of ≥40 kg.
  2. Must have confirmed acute myeloid leukemia (R/R AML) including:

    1. Relapsed AML is defined as ≥5% blasts in the bone marrow (BM) or peripheral blood at any time after achieving a CR, CRh, Cri, or MLFS.
    2. Refractory AML is defined as failure to achieve a CR, CRh, Cri, or MLFS after 1 of the following regimens:

    i. Two courses of intensive induction chemotherapy. ii. At least 2 cycles of hypomethylating agent (HMA) or low-dose, cytarabine-based combination regimen.

    iii. At least 4 cycles of HMA monotherapy.

  3. During dose escalation, participants must be ineligible for hematopoietic stem cell transplantation ().
  4. Must have an anticipated of >3 months before lymphodepletion.
  5. (ECOG) performance status of 0 to 1.
  6. Participants must have adequate renal, cardiac, hepatic, pulmonary and bone marrow function as defined by the protocol.

Exclusion criteria

Exclusion criteria:

  1. Diagnosis of acute promyelocytic leukemia.
  2. Has received or plans to receive any of the excluded therapy/treatment within the specified timeframe before lymphodepleting chemotherapy as defined by the protocol.
  3. Prior HSCT within 3 months of signing form (ICF) or with ongoing requirement for systemic graft-versus-host therapy.
  4. Active central nervous system (CNS) involvement.
  5. History of other than non-melanoma skin cancer or carcinoma in situ (eg. cervix, bladder, breast) low grade prostate cancer without treatment requirement unless in remission without treatment for ≥2 years.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Phase 1: Dose Escalation of GDX012 (Dose Level 1)

    Participants received GDX012 weight-based dose level 1 as an intravenous (IV) infusion on Day 1 of Phase 1, following lymphodepleting chemotherapy. Dose Level 1 was the lowest dose level.

    Drug: GDX012 · Drug: Chemotherapy Agents

  • Experimental
    Phase 1: Dose Escalation of GDX012 (Dose Level 2)

    Participants received GDX012 weight-based dose level 2 as an IV infusion on Day 1 of Phase 1, following lymphodepleting chemotherapy. Dose Level 2 was higher than Dose Level 1.

    Drug: GDX012 · Drug: Chemotherapy Agents

  • Experimental
    Phase 1: Dose Escalation of GDX012 (Dose Level 3)

    Participants received GDX012 weight-based dose level 3 as an IV infusion on Day 1 of Phase 1, following lymphodepleting chemotherapy. Dose Level 3 was higher than Dose Level 2.

    Drug: GDX012 · Drug: Chemotherapy Agents

Interventions

  • DrugGDX012

    GDX012 suspension for IV infusion.

    Also known as: TAK-012

  • DrugChemotherapy Agents

    Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.

07

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs) to Determine the Maximum Tolerated Dose (MTD) of GDX012

    DLTs were defined as events occurring by Day 30 after the first GDX012 infusion considered related to GDX012 if they could not be explained by underlying disease, prior therapy, intercurrent illness, or lymphodepleting chemotherapy. Events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. DLTs included severe non-hematologic toxicities (Grade 3-4, unresolved or involving vital organs), Grade ≥3 graft versus host disease (GvHD) graded per the Mount Sinai Acute GvHD International Consortium recommendations and 2014 National Institutes of Health (NIH) Consensus, Grade 3-4 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) per American Society for Transplantation and Cellular Therapy (ASTCT) criteria, Grade ≥3 infusion reactions or tumor lysis syndrome (TLS), persistent cytopenia or marrow hypocellularity, and any Grade 5 toxicity attributable to GDX012.

    Time frame: Up to 30 days post infusion

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This includes any newly occurring event or a previous condition that has increased in severity or frequency since the administration of study drug. TEAEs are defined as any AE that begins on or after the initiation of treatment with a study intervention or any existing event that worsens following exposure to the study intervention.

    Time frame: Up to 14 months

Secondary outcomes

  1. Percentage of Participants With Disease Response

    Percentage of participants with disease response included participants who achieved complete response (CR), complete response with partial hematologic recovery (CRh), or complete response with incomplete hematologic recovery (CRi), based on responses assessed by the investigator according to the 2022 European Leukemia Net \[ELN\] response criteria for acute myeloid leukemia (AML). CR was defined as the sum of complete remission and complete remission without measurable residual disease (MRD). CRh was defined as the sum of CRh and CRhMRD-. CRi was defined as the sum of CRi and CRiMRD-.

    Time frame: Up to 14 months

  2. Percentage of Participants With Measurable Residual Disease (MRD) Negative Status as Determined by Flow Cytometry

    The MRD negative status was defined as (less than) \<0.1% detectable disease based on local assessment of bone marrow and/or blood.

    Time frame: Up to 14 months

  3. Duration of Response (DOR)

    DOR was planned to be assessed for participants with CR, CRh, or CRi and was defined as the time from the date of first documented CR, CRh, or CRi to the date of first documented relapse or death from any cause, whichever comes first. CR was defined as the sum of Complete Remission and Complete Remission without MRD. CRh was defined as the sum of CRh and CRhMRD-. CRi was defined as the sum of CRi and CRiMRD- .

    Time frame: Up to 14 months

  4. Event-free Survival (EFS)

    EFS was defined as the time from the date of the first GDX012 administration to the date of treatment failure, relapse for those who achieved CR, CRh, or CRi, or death from any cause, whichever came first. CR was defined as the sum of Complete Remission and Complete Remission without MRD (CRMRD-). CRh was defined as the sum of CRh and CRhMRD-. CRi was defined as the sum of CRi and CRiMRD-. EFS was analyzed using the Kaplan-Meier method.

    Time frame: Up to 14 months

  5. Overall Survival (OS)

    OS was defined as the time from the date of the first GDX012 administration to the date of death from any cause. Participants without documentation of death at the time of analysis were censored at the last contact date. OS was analyzed using the Kaplan-Meier method.

    Time frame: Up to 14 months

08

Results

Posted Sep 25, 2026

Participant flow

Participants took part in the study at 10 investigative sites in United States and Japan from 11 July 2023 to 30 November 2025.

Participant flow — Overall Study
MilestonePhase 1: Dose Escalation of GDX012 (Dose Level 1)Phase 1: Dose Escalation of GDX012 (Dose Level 2)Phase 1: Dose Escalation of GDX012 (Dose Level 3)
Started448
Completed000
Not completed448
Withdrew: Death127
Withdrew: Withdrawal by subject201
Withdrew: Reason not specified120

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs) to Determine the Maximum Tolerated Dose (MTD) of GDX012

DLTs were defined as events occurring by Day 30 after the first GDX012 infusion considered related to GDX012 if they could not be explained by underlying disease, prior therapy, intercurrent illness, or lymphodepleting chemotherapy. Events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. DLTs included severe non-hematologic toxicities (Grade 3-4, unresolved or involving vital organs), Grade ≥3 graft versus host disease (GvHD) graded per the Mount Sinai Acute GvHD International Consortium recommendations and 2014 National Institutes of Health (NIH) Consensus, Grade 3-4 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) per American Society for Transplantation and Cellular Therapy (ASTCT) criteria, Grade ≥3 infusion reactions or tumor lysis syndrome (TLS), persistent cytopenia or marrow hypocellularity, and any Grade 5 toxicity attributable to GDX012.

Time frame:
Up to 30 days post infusion
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs) to Determine the Maximum Tolerated Dose (MTD) of GDX012
ParticipantsPhase 1: Dose Escalation of GDX012 (Dose Level 1)Phase 1: Dose Escalation of GDX012 (Dose Level 2)Phase 1: Dose Escalation of GDX012 (Dose Level 3)
Number of Participants With Dose Limiting Toxicities (DLTs) to Determine the Maximum Tolerated Dose (MTD) of GDX012001
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This includes any newly occurring event or a previous condition that has increased in severity or frequency since the administration of study drug. TEAEs are defined as any AE that begins on or after the initiation of treatment with a study intervention or any existing event that worsens following exposure to the study intervention.

Time frame:
Up to 14 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPhase 1: Dose Escalation of GDX012 (Dose Level 1)Phase 1: Dose Escalation of GDX012 (Dose Level 2)Phase 1: Dose Escalation of GDX012 (Dose Level 3)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)338
SecondaryPercentage of Participants With Disease Response

Percentage of participants with disease response included participants who achieved complete response (CR), complete response with partial hematologic recovery (CRh), or complete response with incomplete hematologic recovery (CRi), based on responses assessed by the investigator according to the 2022 European Leukemia Net \[ELN\] response criteria for acute myeloid leukemia (AML). CR was defined as the sum of complete remission and complete remission without measurable residual disease (MRD). CRh was defined as the sum of CRh and CRhMRD-. CRi was defined as the sum of CRi and CRiMRD-.

Time frame:
Up to 14 months
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Response
percentage of participantsPhase 1: Dose Escalation of GDX012 (Dose Level 1)Phase 1: Dose Escalation of GDX012 (Dose Level 2)Phase 1: Dose Escalation of GDX012 (Dose Level 3)
CR0 (0.0 to 70.8)0 (0.0 to 70.8)0 (0.0 to 45.9)
CRh0 (0.0 to 70.8)0 (0.0 to 70.8)0 (0.0 to 45.9)
CRi0 (0.0 to 70.8)0 (0.0 to 70.8)0 (0.0 to 45.9)
SecondaryPercentage of Participants With Measurable Residual Disease (MRD) Negative Status as Determined by Flow Cytometry

The MRD negative status was defined as (less than) \<0.1% detectable disease based on local assessment of bone marrow and/or blood.

Time frame:
Up to 14 months
Reported as:
Number · percentage of participants
Percentage of Participants With Measurable Residual Disease (MRD) Negative Status as Determined by Flow Cytometry
percentage of participantsPhase 1: Dose Escalation of GDX012 (Dose Level 1)Phase 1: Dose Escalation of GDX012 (Dose Level 2)Phase 1: Dose Escalation of GDX012 (Dose Level 3)
Complete Remission without MRD0 (0.0 to 70.8)0 (0.0 to 70.8)0 (0.0 to 45.9)
Complete Remission with Partial Hematologic Recovery without MRD0 (0.0 to 70.8)0 (0.0 to 70.8)0 (0.0 to 45.9)
Complete Remission with Incomplete Hematologic Recovery without MRD0 (0.0 to 70.8)0 (0.0 to 70.8)0 (0.0 to 45.9)
SecondaryDuration of Response (DOR)

DOR was planned to be assessed for participants with CR, CRh, or CRi and was defined as the time from the date of first documented CR, CRh, or CRi to the date of first documented relapse or death from any cause, whichever comes first. CR was defined as the sum of Complete Remission and Complete Remission without MRD. CRh was defined as the sum of CRh and CRhMRD-. CRi was defined as the sum of CRi and CRiMRD- .

Time frame:
Up to 14 months

No measurements were reported for this outcome.

SecondaryEvent-free Survival (EFS)

EFS was defined as the time from the date of the first GDX012 administration to the date of treatment failure, relapse for those who achieved CR, CRh, or CRi, or death from any cause, whichever came first. CR was defined as the sum of Complete Remission and Complete Remission without MRD (CRMRD-). CRh was defined as the sum of CRh and CRhMRD-. CRi was defined as the sum of CRi and CRiMRD-. EFS was analyzed using the Kaplan-Meier method.

Time frame:
Up to 14 months
Reported as:
Median · months
Event-free Survival (EFS)
monthsPhase 1: Dose Escalation of GDX012 (Dose Level 1)Phase 1: Dose Escalation of GDX012 (Dose Level 2)Phase 1: Dose Escalation of GDX012 (Dose Level 3)
Event-free Survival (EFS)0.033 (NA to NA)0.033 (0.033 to NA)0.033 (NA to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of the first GDX012 administration to the date of death from any cause. Participants without documentation of death at the time of analysis were censored at the last contact date. OS was analyzed using the Kaplan-Meier method.

Time frame:
Up to 14 months
Reported as:
Median · months
Overall Survival (OS)
monthsPhase 1: Dose Escalation of GDX012 (Dose Level 1)Phase 1: Dose Escalation of GDX012 (Dose Level 2)Phase 1: Dose Escalation of GDX012 (Dose Level 3)
Overall Survival (OS)5.618 (NA to NA)6.045 (3.154 to NA)3.121 (0.723 to 5.947)

Adverse events

Collected over Up to 14 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Dose Escalation of GDX012 (Dose Level 1)1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Phase 1: Dose Escalation of GDX012 (Dose Level 2)2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Phase 1: Dose Escalation of GDX012 (Dose Level 3)7/8 (87.5%)3/8 (37.5%)8/8 (100%)
Most frequent serious events
Most frequent serious events
EventPhase 1: Dose Escalation of GDX012 (Dose Level 1)Phase 1: Dose Escalation of GDX012 (Dose Level 2)Phase 1: Dose Escalation of GDX012 (Dose Level 3)
Acute graft versus host diseaseImmune system disorders0/31/30/8
Febrile neutropeniaBlood and lymphatic system disorders1/30/31/8
HypervolaemiaMetabolism and nutrition disorders1/30/30/8
PneumoniaInfections and infestations1/30/30/8
SepsisInfections and infestations1/31/30/8
Immune effector cell-associated neurotoxicity syndromeNervous system disorders0/30/31/8
Respiratory failureRespiratory, thoracic and mediastinal disorders0/30/31/8
SinusitisInfections and infestations0/30/31/8
Most frequent other events
Showing 10 of 91
Most frequent other events
EventPhase 1: Dose Escalation of GDX012 (Dose Level 1)Phase 1: Dose Escalation of GDX012 (Dose Level 2)Phase 1: Dose Escalation of GDX012 (Dose Level 3)
EpistaxisRespiratory, thoracic and mediastinal disorders2/30/30/8
HypokalaemiaMetabolism and nutrition disorders1/32/32/8
HypomagnesaemiaMetabolism and nutrition disorders0/32/30/8
ChillsGeneral disorders1/30/34/8
Cytokine release syndromeImmune system disorders0/31/34/8
FatigueGeneral disorders1/31/34/8
NauseaGastrointestinal disorders1/31/34/8
Febrile neutropeniaBlood and lymphatic system disorders0/30/33/8
HypophosphataemiaMetabolism and nutrition disorders1/31/33/8
Abdominal painGastrointestinal disorders1/30/30/8

Baseline characteristics

Intent-to-Treat (ITT) population included all enrolled participants.

Age, Continuous
Age, Continuous(years)Phase 1: Dose Escalation of GDX012 (Dose Level 1)Phase 1: Dose Escalation of GDX012 (Dose Level 2)Phase 1: Dose Escalation of GDX012 (Dose Level 3)Total
Mean62.8 ± 14.5759.3 ± 21.6462.5 ± 10.5661.8 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Dose Escalation of GDX012 (Dose Level 1)Phase 1: Dose Escalation of GDX012 (Dose Level 2)Phase 1: Dose Escalation of GDX012 (Dose Level 3)Total
Female4138
Male0358
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Dose Escalation of GDX012 (Dose Level 1)Phase 1: Dose Escalation of GDX012 (Dose Level 2)Phase 1: Dose Escalation of GDX012 (Dose Level 3)Total
Hispanic or Latino0000
Not Hispanic or Latino34815
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: Dose Escalation of GDX012 (Dose Level 1)Phase 1: Dose Escalation of GDX012 (Dose Level 2)Phase 1: Dose Escalation of GDX012 (Dose Level 3)Total
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White24713
More than one race0000
Unknown or Not Reported1001
09

Study locations

11 sites
  • University of Alabama at Birmingham (UAB) Hospital
    Birmingham, Alabama 35205, United States
  • City of Hope
    Duarte, California 91010, United States
  • Sarah Cannon/CBCI
    Denver, Colorado 80218, United States
  • Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois 60611, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • Thomas Jefferson University
    New York, New York 10065, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Tri-Star BMT/Sarah Cannon Nashville
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • National Cancer Center Hospital East
    Kashiwa, 277-8577, Japan
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Aug 2025, 25 months.

Results were first posted in Sep 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2023
First posted
Jun 2, 2023
StartActual
Jul 11, 2023
Primary completionActual
Aug 20, 2025
CompletionActual
Nov 30, 2025
Results first posted
Sep 25, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 25, 2026
Interventions
Arm changed Phase 1: Dose Escalation of GDX012→Phase 1: Dose Escalation of GDX012 (Dose Level 1). Arms added: Phase 1: Dose Escalation of GDX012 (Dose Level 2)·Phase 1: Dose Escalation of GDX012 (Dose Level 3); arms removed: Phase 2a: GDX012
Sep 25, 2026
Primary outcomes
2 edited, 1 removed
What changed in the outcomes
  • EditedNumber of Participants With Dose Limiting Toxicities (DLTs) to Determine the Maximum Tolerated Dose (MTD) of GDX012Time frame: Up to 1 month → Up to 30 days post infusion
  • EditedNumber of Participants With Treatment-Emergent Adverse Events (AEsTEAEs)Time frame: Up to 14 months
  • RemovedMaximum Tolerated Dose (MTD) of GDX012Time frame: Up to 1 month
Sep 25, 2026
Documents
Secondary outcomes
2 edited, 3 description edited
What changed in the outcomes
  • EditedNumberPercentage of Participants With Disease ResponseTime frame: Up to 14 months
  • EditedNumberPercentage of Participants With Measurable Residual Disease (MRD) Negative Status as Determined by Flow CytometryTime frame: Up to 14 months
  • DescriptionDuration of Response (DOR): how it is measured was reworded
  • DescriptionEvent-free Survival (EFS): how it is measured was reworded
  • DescriptionOverall Survival (OS): how it is measured was reworded
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Results posted
    Primary outcomes 2 edited, 1 removed
    What changed in the outcomes
    • EditedNumber of Participants With Dose Limiting Toxicities (DLTs) to Determine the Maximum Tolerated Dose (MTD) of GDX012Time frame: Up to 1 month → Up to 30 days post infusion
    • EditedNumber of Participants With Treatment-Emergent Adverse Events (AEsTEAEs)Time frame: Up to 14 months
    • RemovedMaximum Tolerated Dose (MTD) of GDX012Time frame: Up to 1 month
    Secondary outcomes 2 edited, 3 description edited
    What changed in the outcomes
    • EditedNumberPercentage of Participants With Disease ResponseTime frame: Up to 14 months
    • EditedNumberPercentage of Participants With Measurable Residual Disease (MRD) Negative Status as Determined by Flow CytometryTime frame: Up to 14 months
    • DescriptionDuration of Response (DOR): how it is measured was reworded
    • DescriptionEvent-free Survival (EFS): how it is measured was reworded
    • DescriptionOverall Survival (OS): how it is measured was reworded
    Interventions Arm changed Phase 1: Dose Escalation of GDX012→Phase 1: Dose Escalation of GDX012 (Dose Level 1). Arms added: Phase 1: Dose Escalation of GDX012 (Dose Level 2)·Phase 1: Dose Escalation of GDX012 (Dose Level 3); arms removed: Phase 2a: GDX012
    + 5 other changes: verification date, description, contact details, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05886491
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jun 2, 2023
Start date
Jul 11, 2023
Primary completion
Aug 20, 2025
Completion
Nov 30, 2025
Results posted
Sep 25, 2026
Last update
Sep 25, 2026

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion